ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO825

Clinical Associations with Serum Syndecan-1 Level in Patients with Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Yung, Susan, The University of Hong Kong, Hong Kong, China
  • Yu, Kelvin, The University of Hong Kong, Hong Kong, China
  • Chau, Mel, The University of Hong Kong, Hong Kong, China
  • Cheung, Kwok Fan, The University of Hong Kong, Hong Kong, China
  • Chan, Daniel Tak Mao, The University of Hong Kong, Hong Kong, China

Cardiovascular disease is an important long-term complication in patients with lupus nephritis. The endothelial glycocalyx regulates the adhesiveness of circulating cells to vascular endothelial cells and vascular permeability. Syndecan-1 is a component of the endothelial glycocalyx, and syndecan-1 shedding occurs in endothelial cell activation or injury.


Serial serum samples from patients with biopsy-proven Class III/IV lupus nephritis were obtained at intervals of 3-4 months over two years. In addition, paired samples with one obtained during flare and the other during remission were included. Sera from age- and sex-matched patients with IgA nephropathy (IgAN), SLE patients without nephritis, and healthy subjects were included as controls (n=25 for each group). Serum syndecan-1 level was determined by ELISA.


Four hundred and sixty sera from 29 lupus nephritis patients (20 females and 9 males; age 39.0±10.2 years; disease duration 7.6±8.6 years) were studied. Serum syndecan-1 level was significantly higher during active lupus nephritis compared with remission, and also the IgAN, non-renal lupus, and healthy control groups (P<0.001, for all). Syndecan-1 level correlated with SLEDAI (r=0.535, P<0.001), anti-dsDNA antibody level (r=0.407, P=0.003), serum creatinine level (r=0.262, P=0.05), proteinuria (r=0.571, P<0.001), and inversely correlated with serum C3 (r=-0.443, P=0.001) and albumin levels (r=-0.568, P<0.001). Circulating syndecan-1 level showed a temporal relationship with disease activity and changes in anti-dsDNA antibody and C3 levels. ROC curve analysis showed that serum syndecan-1 level distinguished active lupus nephritis from healthy subjects with sensitivity and specificity rates of 96.3% and 96.0% respectively, from IgAN patients with respective rates of 85.2% and 91.3%, and from non-renal lupus patients with respective rates of 85.7% and 70.4% (P<0.0001, for all).


Active lupus nephritis is associated with increased circulating syndecan-1 level, and thus may contribute towards the pathogenesis of cardiovascular complications in patients with lupus nephritis.


  • Government Support - Non-U.S.